EUCTR2011-001528-39-SE进行中（未招募）不适用
A Double-blind, Randomized, Placebo-controlled, Multicenter Study toEvaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects withHeterozygous Familial Hypercholesterolemia - Reduction of LDL-C with PCSK9 inhibition in HeFH Disorder Study [RUTHERFORD]
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject has provided informed consent
- •- Male or female = 18 to = 75 years of age
- •- Diagnosis of heterozygous familial hypercholesterolemia by having met the diagnostic criteria outlined by the Simon Broome Register Group (Scientific Steering Committee 1991) as defined by the documentation of one of the following in the patient’s past medical record:
- •1. A total cholesterol concentration > 290 mg/dL (> 7.5 mmol/liter) in
- •adulthood or a total cholesterol concentration > 260 mg/dL
- •(> 6.7 mmol/liter) in childhood at an age of less than 16 years, or a
- •LDL-C concentration > 190 mg/dL (> 4.9 mmol/liter) in adulthood or
- •> 155 mg/dL (> 4.0 mmol/liter) in childhood AND Tendinous
- •xanthomas in the patient or first- or second-degree relative
- •2. Deoxyribonucleic acid (DNA)-based evidence of mutation in the
- •LDLR, ApoB, or PCSK9 gene
- •3. A total cholesterol concentration > 290 mg/dL (> 7.5 mmol/liter) in
- •adulthood or a total cholesterol concentration > 260 mg/dL
- •(> 6.7 mmol/liter) in childhood at an age of less than 16 years, or a
- •LDL-C concentration > 190 mg/dL (> 4.9 mmol/liter) in adulthood or
- •> 155 mg/dL (> 4.0 mmol/liter) in childhood AND family history of
- •myocardial infarction before age 50 years in a second-degree
- •relative or before age 60 years in a first-degree relative
- •4. A total cholesterol concentration > 290 mg/dL (> 7.5 mmol/liter) in
- •adulthood or a total cholesterol concentration > 260 mg/dL
- •(> 6.7 mmol/liter) in childhood at an age of less than 16 years, or a LDL-C concentration > 190 mg/dL (> 4.9 mmol/liter) in adulthood or
- •> 155 mg/dL (> 4.0 mmol/liter) in childhood AND family history of
- •raised total cholesterol concentration > 290 mg/dL (> 7.5 mmol/liter)
- •in a first or second-degree adult relative or > 260 mg/dL
- •(> 6.7 mmol/liter) in child, brother, or sister aged younger than
- •- On an approved statin, with stable dose(s) for all allowed (eg, ezetimibe,
- •bile-acid sequestering resin, stanols, or regulatory-approved and
- •marketed niacin (eg, Niaspan or Niacor)) lipid-regulating drugs for at least 4 weeks before LDL-C screening, and in the opinion of the
- •investigator, not requiring uptitration
- •- Fasting LDL-C = 100 mg/dL (2.6 mmol/liter) by central laboratory at screening
- •- Fasting triglycerides = 400 mg/dL (4.5 mmol/liter)by central laboratory at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •- Homozygous familial hypercholesterolemia
- •- LDL or plasma apheresis within 12 months prior to randomization
- •- NYHA III or IV heart failure, or last known left ventricular ejection fraction < 30%
- •- Uncontrolled serious cardiac arrhythmia defined as recurrent and highly
- •symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
- •- Myocardial infarction, unstable angina, percutaneous coronary
- •intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
- •- Planned cardiac surgery or revascularization within 20 weeks of
- •- Type 1 diabetes or newly diagnosed (within 3 months of randomization) type 2 diabetes, or poorly controlled type 2 diabetes (HbA1c > 8.5%)
- •- Uncontrolled hypertension defined as sitting systolic blood pressure
- •(SBP) > 160 mmHg or diastolic BP (DBP) > 100 mmHg, confirmed with
- •repeat measurement
- •- Subject requires uptitration of their current statin dose (these subjects can be uptitrated and rescreened one month later).
- •- Subject has taken in the last 6 weeks prior to LDL-C screening red
- •yeast rice, omega-3 fatty acids ([eg, DHA and EPA] [> 1000 mg/day])
- •or prescription lipid-regulating drugs (eg, fibrates and derivatives)
- •other than statins, ezetimibe, bile-acid sequestering resin, stanols,
- •or regulatory approved and marketed niacin (eg, Niaspan or Niacor)
- •- Treatment in the last 3 months prior to LDL-C screening with any of the following drugs: systemic cyclosporine, systemic steroids (IV, intramuscular [IM], or PO), vitamin A derivatives and retinol derivatives for the treatment of dermatologic conditions (eg, Accutane); (Note: vitamin A in a multivitamin preparation is permitted)
- •- Hyperthyroidism or hypothyroidism as defined by thyroid stimulating
- •hormone (TSH) below the lower
- •limit of normal (LLN) or >1.5 times the upper limit of normal (ULN),
- •respectively, at screening
- •- Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 at screening
- •- Active liver disease or hepatic dysfunction, defined as aspartate
- •aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the ULN as determined by central laboratory analysis at screening
- •- CK > 3 times the ULN at screening, confirmed by a repeat measurement at least 1 week apart
- •- Known active infection or major hematologic, renal, metabolic,
- •gastrointestinal or endocrine dysfunction in the judgment of the
- •investigator
- •- Diagnosis of deep vein thrombosis or pulmonary embolism within
- •3 months prior to randomization
- •- Current therapeutic anticoagulation with vitamin K antagonist (eg,
- •warfarin), heparin, low-molecular weight heparin, direct thrombin inhibitor, or Factor Xa inhibitor (Note: anti-platelet agents [eg, aspirin, clopidogrel, prasugrel, ticagrelor, dipyridamole] are permitted).
- •- Unreliability as a study participant based on the investigator's (or
- •designee’s) knowledge of the subject (eg, alcohol or other drug abuse,
- •inability or unwillingness to adhere to the protocol, or psychosis)
- •- Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)
- •- Female subject who is not willing to use at least one highly effective method of birth contr
研究者
相似试验
进行中（未招募）
1 期
Study to assess the tolerability and efficacy of AMG 145 in patients withheterozygous familial hypercholesterolemiaHeterozygous Familial HypercholesterolemiaMedDRA version: 14.1Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2012-001365-32-NLAmgen Inc331
进行中（未招募）
1 期
Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced.Chronic Heart Failure and Left Ventricular Systolic DysfunctionMedDRA version: 17.0Level: PTClassification code 10063083Term: Chronic left ventricular failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-000327-40-BEAmgen Inc.570
进行中（未招募）
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersDyslipidemiaEUCTR2018-004565-14-PLAmgen Inc.12,000
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseDyslipidemiaMedDRA version: 19.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2012-001398-97-LTAmgen Inc27,500
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailureAcute heart failureMedDRA version: 14.1Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-021003-24-LTAmgen Inc600